
    
      Primary objective : Retrospectively collect and describe the real life efficacy (SVR 12)* and
      safety data of EBR 50 mg/GZR 100 mg based therapy, 12 or 16 weeks dosed in HCV-infected
      patients with chronic kidney disease. These data are collected following French ATU
      allocation.
    
  